English
Français
Español
Deutsch
Italiano
Português
Nederlands
Polski
Română
Svenska
Dansk
Suomi
Čeština
Ελληνικά
Magyar
SlovenčinaData temporarily unavailable
Unable to load analysis for « - » for now. Try again in a few moments.
Investlytic score: 3/5 criteria met.
- ✅ Price trend passed
- ✅ Growth passed
- ❌ Debt failed
- ❌ P/E failed
- ✅ Correction passed
Price trend
Overall trend (8 years): the price has been multiplied by at least 1.5.
Price change 2018 → 2019: 38.18%
Price change 2019 → 2020: -7.63%
Price change 2020 → 2021: 71.30%
Price change 2021 → 2022: -31.14%
Price change 2022 → 2023: -26.45%
Price change 2023 → 2024: -23.15%
Price change 2024 → 2025: 126.50%
Price change 2025 → 2026: 9.67%
Price change 2026 (year to date): 9.15%
Financial growth
Revenue CAGR (8 years): 12.25%
Earnings CAGR (8 years): 8.18%
Growth status: positive trend (>1%/yr) in revenue and earnings.
Debt
Debt-to-equity ratio: 0.71
Debt/equity > 0.5 (maximum threshold).
P/E (Price/Earnings)
P/E ratio: 38.15
P/E > 25.0 (maximum threshold).
Correction (6 months)
Current correction: 18.42% from the high over 6 months.
Correction between 10.0% and 20.0% (target range).
Criteria of the Investlytic model
- / 5Price trend
Price & trend
Interactive chart →💰 Dividend
Dividend ranking →⚖️ Comparison with the market
All stocks →| Stock | P/E | Dette/FP | Revenue growth | Rating |
|---|---|---|---|---|
| Lumibird S.A. | 37.3 | 0.71 | +9.8 % | 🔒 |
| Valneva SE | – | 1.95 | +22.4 % | – |
| Clariane SE | 565.5 | 2.16 | +12.4 % | – |
| Transgene S.A. | – | 0.02 | −20.1 % | – |
| Emeis | – | 6.11 | +11.4 % | – |
Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.
Detailed analysis · Price trend
-
Revenues & profits
Revenue and net income
Financial indicators
Annual financial statements
| Fiscal year | Revenue | Net income | Net margin | EPS | Revenue growth |
|---|